



CLINICAL TRIAL ADVANCES IN ANTIFUNGAL PHARMACOTHERAPY: EFFICACY, SAFETY AND RESISTANCE TRENDS

¹Shruti Sanjay Joshi , ²Vishakha Patil , ³Smital Gondkar, ⁴Ashwini pagar

¹ UG student , department of B. pharmacy pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra
¹Mr. Vikas Kunde ,

¹Assistant professor, department of B. pharmacy pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

Abstract: Invasive fungal infections (IFI) are now recognized as a serious global health threats placing a heavy burden on health care system. Treating thus infections is difficult because the available antifungal drugs often cause side effects , have limited effectiveness and face rising resistance. Over the past 30 years, researchers have carried out extensive testing of antifungal drugs. These efforts have been crucial in creating treatment guidelines for serious fungal infections.

Most of these guidelines are based on well known and highly cited clinical trials. While we have made progress in developing antifungal medicines that are more effective and less toxic than older options .Early detections and targeted treatment This growing challenge highlights the urgent need for new antifungal medications. This review explores the latest advancements in antifungal drug development, focusing on innovative compounds that are either being tested in clinical trials or are likely to be evaluated soon. These new agents stand out because of their novel mechanisms of action, broader antimicrobial coverage, and improved pharmacokinetic properties. Together, these qualities hold promise for more effective treatment options than traditional drugs.

Index : Invasive fungal infections (IFIs), Global health concern, Drug resistance, Clinical trials, Pharmacokinetics, Improved patient outcomes -

I. INTRODUCTION

Fungi are an incredibly diverse group of microorganisms. Out of thousands of species, only about 300 are known to cause disease in humans — but those that do can be very serious, even life-threatening. In recent years, fungal infections have been gaining attention as a growing public health concern. In 2023 alone, fungal diseases were estimated to have caused around **2.5 million deaths worldwide**. They are especially dangerous for people with weakened immune systems.

Currently, we treat fungal infections with four main types of drugs — **polyenes, azoles, echinocandins, and pyrimidine analogues**. While they can be effective, they also have significant limitations. Many fungi have developed resistance to them, and some drugs can be toxic or have poor pharmacokinetic properties, meaning they don't travel through the body efficiently.

Conventional antifungal drugs remain a cornerstone of fungal infection treatment. The most widely used classes are **polyenes, azoles, allylamines, echinocandins, and pyrimidine analogues**. Each class works differently to stop fungal growth, and each has its own clinical strengths and limitations.

Polyenes

Polyenes work by binding directly to **ergosterol**, a crucial component of fungal cell membranes. This binding punches holes in the membrane, allowing cell contents to leak out, which ultimately kills the fungus.

□

- **Amphotericin B** is the classic example, often reserved for life-threatening infections such as cryptococcal meningitis and invasive aspergillosis. It's very effective but has a major drawback — serious kidney toxicity — which limits its long-term use.

- **Nystatin** is mostly used for *Candida* infections of the mouth or vagina. It's generally applied topically since it's too toxic for systemic use, but it's safe when used locally.

Azoles

Azoles stop fungi from making ergosterol by blocking the enzyme **14- α -demethylase**. Without ergosterol, the membrane becomes unstable and fungal growth is halted.

- **First-generation azoles** like **ketoconazole** are now mostly used topically due to the risk of serious liver damage.
- **Second-generation azoles** like **fluconazole** and **itraconazole** are used much more often.
 - *Fluconazole* is widely prescribed for *Candida* infections and cryptococcal meningitis, though it's less effective against certain resistant *Candida* strains (*C. glabrata* and *C. krusei*). Liver toxicity is still a possible concern.
 - *Itraconazole* treats skin infections and some invasive fungal diseases, but its absorption can vary depending on the patient and even on what they've eaten, making dosing tricky.

Allylamines

Allylamines — such as **terbinafine** and **naftifine** — block **squalene epoxidase**, another key enzyme in the ergosterol-making process. Without ergosterol, the fungal cell membrane falls apart, leading to cell death. They're most often prescribed for skin and nail infections like athlete's foot, ringworm, and onychomycosis. Liver toxicity is possible, so patients are usually monitored during longer treatments.

Echinocandins

Echinocandins, including **caspofungin** and **micafungin**, target **β -(1,3)-D-glucan synthase**, an enzyme fungi need to build their cell walls. Without a proper cell wall, the fungus becomes fragile and dies. These drugs are especially valuable for invasive *Candida* and *Aspergillus* infections. While generally well tolerated, they can raise liver enzymes and sometimes cause infusion-related reactions. Resistance can occur through mutations in the **FKS** genes that alter the drug's binding site.

Pyrimidine Analogues

Flucytosine works inside the fungal cell, disrupting both DNA and RNA production, which stops the fungus from multiplying. It's rarely used alone — instead, it's combined with amphotericin B for cryptococcal meningitis, which boosts effectiveness and lowers resistance risk. Long-term use can suppress bone marrow function, so blood counts must be monitored.

Limitations of Traditional Antifungals

While these drugs are essential, each class comes with its own challenges — whether it's toxicity, resistance, or inconsistent absorption. With resistant fungal strains on the rise and more patients needing complex antifungal care, the shortcomings of these older drugs are becoming clearer

1. Traditional Antifungal Drugs

Drug/Class	Efficacy Highlights
Amphotericin B (Polyenes)	Highly effective for severe systemic infections like cryptococcal meningitis and B invasive aspergillosis; broad-spectrum activity against most pathogenic fungi; nephrotoxicity limits prolonged use. Effective for topical treatment of oral and vaginal <i>Candida</i> infections; minimal systemic toxicity.
Nystatin (Polyenes)	Effective for topical treatment of oral and vaginal <i>Candida</i> infections; minimal systemic toxicity.
Fluconazole (Azoles)	Good activity against most <i>Candida</i> species and cryptococcal meningitis; limited efficacy against <i>C. glabrata</i> and <i>C. krusei</i> .
Itraconazole (Azoles)	Effective for dermatophytosis, some invasive fungal infections; efficacy can vary due to unpredictable absorption.
Terbinafine (Allylamines)	Very effective for dermatophyte skin and nail infections; fungicidal against most dermatophytes.
Caspofungin & Micafungin (Echinocandins)	Strong activity against <i>Candida</i> (including azole-resistant strains) and <i>Aspergillus</i> ; minimal activity against <i>Cryptococcus</i> .
Flucytosine (Pyrimidine analogue)	Effective in combination with amphotericin B for cryptococcal meningitis; enhances treatment outcomes and delays resistance onset.

2. Novel / Next-Generation Antifungal Drugs

Drug/Class	Efficacy Highlights
Ibrexafungerp	Broad-spectrum activity against <i>Candida</i> , including echinocandin- and azoleresistant strains (<i>C. auris</i>); effective in murine and rabbit models; FDA-approved for vulvovaginal candidiasis (VVC) and recurrent VVC; higher cure and eradication rates than placebo in clinical trials.
Rezafungin	Strong activity against <i>Candida</i> and <i>Aspergillus</i> , including resistant strains; prolonged half-life allows weekly dosing; Phase III trials show non-inferiority to caspofungin.
Nikkomyacin Z	Potent against <i>Histoplasma</i> , <i>Coccidioides</i> , <i>Blastomyces</i> , <i>Sporothrix</i> , <i>Candida</i> , <i>Aspergillus</i> ; superior to azoles and amphotericin B in animal models for coccidioidomycosis and blastomycosis; synergistic with echinocandins and azoles.
Fosmanogepix	Active against broad range of fungi including azole-resistant <i>Aspergillus</i> and echinocandin-resistant <i>Candida</i> ; reduces fungal burden in lung and brain models; synergistic with amphotericin B.
Jawsamycin	Potent against <i>Mucor</i> , <i>Fusarium</i> , <i>Trichosporon</i> ; improves survival in mouse mucormycosis model; no toxicity at high concentrations in human cell lines.

- Opelconazole** Strong inhaled activity against *Aspergillus*; sustained lung exposure; synergistic with systemic triazoles; promising for invasive pulmonary aspergillosis.
- Isavuconazole** Broad-spectrum; effective against *Aspergillus*, *Candida*, *Fusarium*, *Cryptococcus*; improves survival and reduces fungal load in animal models, including azoleresistant strains.
- VT-1598** Broad-spectrum; effective against yeasts, molds, endemic fungi; good CNS penetration and activity in coccidioidomycosis and cryptococcosis models; active against fluconazole-resistant *Candida*.
- Oteseconazole (VT-1161)** Highly active against *Candida* species, including resistant strains; FDA-approved for recurrent VVC; effective in coccidioidomycosis models.

Aureobasidin A Drug/Class Potent against *Candida* and *Aspergillus*; enhances amphotericin B efficacy in cryptococcal meningitis models.

Efficacy Highlights

Encochleated Amphotericin B (MAT2203) Oral formulation with efficacy comparable to standard amphotericin B but lower toxicity; 100% survival in animal candidiasis models; reduces fungal burden in multiple organs.

Resistance Impact on Efficacy

- Resistance mechanisms include:
 - Genetic mutations altering drug targets.
 - Overexpression of efflux pumps.
 - Biofilm formation, which shields fungi from drug penetration.
 - Metabolic adaptation to reduce dependence on the targeted pathway.
- These mechanisms reduce drug susceptibility, leading to treatment failure.

Antifungal Drug Resistance Overview

Drug Class	Mechanism of Resistance	Example	Resistant Impact on Treatment Fungi
Azoles (fluconazole, itraconazole, voriconazole, isavuconazole)	- Mutations in ERG11 (target enzyme) → prevents drug binding - Efflux pump overexpression → drug pumped out of cell - Biofilm formation	<i>Candida auris</i> , <i>Candida glabrata</i>	- Higher failure rates in invasive infections - Limited oral treatment options (voriconazole)
Polyenes (amphotericin B)	- Altered ergosterol biosynthesis → reduced drug binding - Loss of first-line species	<i>Candida lusitanae</i>	- Reduced susceptibility - Higher relapse rates
Echinocandins (caspofungin, micafungin)	- Mutations in FKS1/FKS2 (β-(1,3)-glucan synthase genes) - Mutations in FCY1/FCY2 genes	<i>Candida glabrata</i> , <i>Candida krusei</i> <i>Cryptococcus</i>	- Rapid resistance

→ **Pyrimidine analogues**
 disrupt drug *neoformans*, *Candida* development if used as
 uptake/metabolism (flucytosine) spp. monotherapy

SAFETY OF ANTIFUNGAL DRUGS

Safety of Traditional Antifungal Drugs
 Polyenes (e.g., Amphotericin B)

Safety Concerns: Notoriously associated with nephrotoxicity (kidney damage) and infusion-related reactions such as fever and chills.

Improvements: Liposomal formulations have reduced toxicity but still require close monitoring.

Azoles (e.g., Fluconazole, Itraconazole, Voriconazole)

Side Effects: Can cause hepatotoxicity (liver injury), gastrointestinal disturbances, and drug–drug interactions due to CYP450 enzyme inhibition.

Voriconazole, in particular, has visual disturbances and neurological side effects.

Echinocandins (e.g., Caspofungin)

Generally Safe: Minimal side effects, well tolerated.

Rare Reactions: Mild liver enzyme elevations and histamine-like reactions with rapid infusion.

Flucytosine

High Toxicity Risk when used alone; causes bone marrow suppression, hepatotoxicity, and gastrointestinal issues.

Always used in combination (e.g., with Amphotericin B) to reduce resistance and toxicity.

General Issues

Limited efficacy of current antifungals is strongly linked to toxicity as well as resistance

Structural similarities between fungal and human cells make it difficult to find selective targets, increasing the risk of host toxicity

Specific Drug Class Safety Concerns

Drug Class	Major Safety Issue	Notes
Azoles (e.g., fluconazole, voriconazole)	Hepatotoxicity	Can cause liver injury due to similarity between fungal ergosterol synthesis and human cholesterol metabolism
Polyenes (e.g., amphotericin B)	Nephrotoxicity	Kidney toxicity reduced with liposomal formulations (e.g., AmBisome®)
Echinocandins	Generally well tolerated	Few systemic toxicities reported, but IV administration can cause infusion-related reactions.
Pyrimidine analogues (e.g., flucytosine)	Bone marrow suppression	Risk increases with prolonged therapy or renal impairment.

Drug-Drug Interactions

Azoles strongly interact with human cytochrome P450 enzymes, leading to potentially dangerous interactions with other drugs

Safety in Nanomedicine Formulations

Liposomal and polymeric nanoparticle formulations improve safety by:

Targeting drug delivery.

Reducing off-target effects.

Allowing higher therapeutic dosing

CONCLUSION

Fungal infections are becoming harder to treat due to rising drug resistance, limited treatment options, and the complexity of fungal biology. Although current antifungal drugs have helped manage many infections, their limitations are now evident.

The development of next-generation antifungals marks a major step forward. These new agents bring fresh mechanisms, improved delivery systems, and broader activity against resistant fungi. Innovations like oral echinocandins, first-in-class orotomides, and mitochondrial disruptors are paving the way for more effective and targeted treatments.

Continued research, faster clinical trials, and global collaboration will be key in bringing these promising drugs to the patients who need them most. With the right support, we may soon have the tools to overcome fungal resistance and greatly improve patient outcomes.

ACKNOWLEDEMENT

The authors would like to express their heartfelt gratitude to their respected guides and mentors for their invaluable support, encouragement, and constructive feedback throughout the preparation of this review. We sincerely thank our institution for providing access to resources and literature that greatly facilitated this work. Our appreciation also goes to all researchers whose studies have been cited, as their contributions form the backbone of this review. Lastly, we are deeply grateful to our family and friends for their constant motivation and encouragement.

REFERENCE

1. Abdallah, B.M., Ali, E.M., 2022. Therapeutic effect of green synthesized silver nanoparticles using erodium glaucophyllum extract against oral candidiasis: in vitro and in vivo study. *Molecules* 27, 4221.
2. Aghaei, M., Kianpour, M., Mardanian, F., Farahbod, F., Fahami, F., Ghahremantermeh, M., 2023. Evaluation of the therapeutic effect of 15 ppm silver nanoparticle spray compared to clotrimazole 1% on candida vaginitis: a randomized controlled clinical trial. *J Family Reprod Health* 17, 255–263.
3. Akinosoglou, K., Rigopoulos, E.A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C., Dimopoulos, G., 2024. Amphotericin B in the era of new antifungals: where will it stand? *J Fungi (basel)* 10, 278.
4. Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J.D., Hoenigl, M., Salzer, H.J.F., Ilkit, M., Lass-Floerl, C., Perlin, D.S., 2020. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. *Antibiotics (basel)* 9, 877.
5. Athie-García, M.S., Piñón-Castillo, H.A., Muñoz-Castellanos, L.N., Ulloa-Ogaz, A.L.,

Martínez-Varela, P.I., Quintero-Ramos, A., Duran, R., Murillo-Ramirez, J.G., Orrantia-Borunda, E., 2018. Cell wall damage and oxidative stress in *Candida albicans* ATCC10231 and *Aspergillus niger* caused by palladium nanoparticles.

6. Toxicol. In Vitro 48, 111–120. Attarilar, S., Yang, J., Ebrahimi, M., Wang, Q., Liu, J., Tang, Y., Yang, J., 2020. The toxicity phenomenon and the related occurrence in metal and metal oxide nanoparticles: a brief review from the biomedical perspective. Front. Bioeng. Biotechnol. 8, 822.

7. Babele, P.K., Thakre, P.K., Kumawat, R., Tomar, R.S., 2018. Zinc oxide nanoparticles induce toxicity by affecting cell wall integrity pathway, mitochondrial function and lipid homeostasis in *Saccharomyces cerevisiae*. Chemosphere 213, 65–75.

8. Bains, A., Narang, D., Chawla, P., Dhull, S.B., 2020. Nanoparticles and antibiotic drug composite: a novel approach towards antimicrobial activity, Nanotechnological Approaches in Food Microbiology, 1st ed. CRC Press, pp. 165–186.

9. Bharathi, D., Lee, J.-H., Lee, J., 2024. Enhancement of antimicrobial and antibiofilm activities of liposomal fatty acids. Colloids Surf. B Biointerfaces 234, 113698. Brown, G.D., Ballou, E.R., Bates, S., Bignell, E.M., Borman, A.M., Brand, A.C., Brown, A.J.

10. P., Coelho, C., Cook, P.C., Farrer, R.A., Govender, N.P., Gow, N.A.R., Hope, W., Hoving, J.C., Dangarembizi, R., Harrison, T.S., Johnson, E.M., Mukaremera, L., Ramsdale, M., Thornton, C.R., Usher, J., Warris, A., Wilson, D., 2024. The pathobiology of human fungal infections. Nat. Rev. Microbiol. 22, 687–704.

11. Calvo, N.L., Sreekumar, S., Svetaz, L.A., Lamas, M.C., Moerschbacher, B.M., Leonardi, D., 2019. Design and characterization of chitosan nanoformulations for the delivery of antifungal agents. Int. J. Mol. Sci. 20, 3686.

12. Carmo, A., Rocha, M., Pereirinha, P., Tomé, R., Costa, E., 2023. Antifungals: from pharmacokinetics to clinical practice. Antibiotics (basel) 12, 884. Casadevall, A., Coelho, C., Cordero, R.J.B., Dragotakes, Q., Jung, E., Vij, R., Wear, M.P., 2019. The capsule of *Cryptococcus neoformans*. Virulence 10, 822–831.

Cdc, 2019. Antibiotic Resistance Threats in the United States. US Department of Health and Human Services, Atlanta, GA, USA.

13. Chandrakala, V., Aruna, V., Angajala, G., 2022. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Mater 5, 1593–1615. Chavan, N.L., Young, J.K., Drezek, R.A., Lewis, R., Bikram, M., 2012. Interactions of liposome carriers with infectious fungal hyphae reveals the role of β -glucans. Mol. Pharm. 9, 2489–2496.

14. Cheeseman, S., Christofferson, A.J., Kariuki, R., Cozzolino, D., Daeneke, T., Crawford, R. J., Truong, V.K., Chapman, J., Elbourne, A., 2020. Antimicrobial metal nanomaterials: from passive to stimuli-activated applications. Adv Sci (weinh) 7, 1902913.

15. Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., Wang, L., 2023. Confronting antifungal resistance, tolerance, and persistence: advances in drug

target discovery and delivery systems. *Adv. Drug Deliv. Rev.* 200, 115007.

16. Chintalacharuvu, K.R., Matolek, Z.A., Pacheco, B., Carriera, E.M., Beenhouwer, D.O., 2021. Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with *Cryptococcal neoformans*. *Med. Mycol.* 59, 1085–1091.
17. Chung, H., Lee, H., Han, H.K., An, H., Lim, K.S., Lee, Y.J., Cho, J.Y., Yoon, S.H., Jang, I.J., Yu, K.S., 2015. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. *Drug Des. Devel. Ther.* 9, 2609–2616.
18. Ciurea, C.N., Kosovski, I.B., Mare, A.D., Toma, F., Pinteá-Simon, I.A., Man, A., 2020. *Candida* and candidiasis-opportunism versus pathogenicity: a review of the virulence traits. *Microorganisms* 8, 857.
19. Contini, C., Schneemilch, M., Gaisford, S., Quirke, N., 2018. Nanoparticle–membrane interactions. *J. Exp. Nanosci.* 13, 62–81.
Cortés, J.C.G., Curto, M.
20. A., Carvalho, V.S.D., Pérez, P., Ribas, J.C., 2019. The fungal cell wall as a target for the development of new antifungal therapies. *Biotechnol. Adv.* 37, 107352.
21. Dananjaya, S.H.S., Thu Thao, N.T., Wijerathna, H.M.S.M., Lee, J., Edussuriya, M., Choi, D., Saravana Kumar, R., 2020. In vitro and in vivo anticandidal efficacy of green synthesized gold nanoparticles using *Spirulina maxima* polysaccharide. *Process Biochem.* 92, 138–148.
22. das Neves, J., Sverdlov Arzi, R., Sosnik, A., 2020. Molecular and cellular cues governing nanomaterial-mucosae interactions: from nanomedicine to nanotoxicology. *Chem. Soc. Rev.* 49, 5058-5100.
23. Dash, S.K., Benival, D., Jindal, A.B., 2024. Formulation strategies to overcome amphotericin B induced toxicity. *Mol. Pharm.* 21, 5392–5412.
Denning, D.W., 2024. Global incidence and mortality of severe fungal disease. *Lancet*
Hwang, I.-S., Lee, J., Hwang, J.H., Kim, K.-J., Lee, D.G., 2012. Silver nanoparticles induce apoptotic cell death in *Candida albicans* through the increase of hydroxyl radicals. *FEBS J.* 279, 1327–1338.
24. Ibe, C., Munro, C.A., 2021. Fungal cell wall: an underexploited target for antifungal therapies. *PLoS Pathog.* 17, e1009470.
Ing, L.Y., Zin, N.M., Sarwar, A., Katas, H., 2012. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. *Int J Biomater* 2012, 632698.
25. Iyer, K.R., Revie, N.M., Fu, C., Robbins, N., Cowen, L.E., 2021. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. *Nat. Rev. Microbiol.* 19, 454–466.
26. Jebali, A., Hajjar, F.H., Pourdanesh, F., Hekmatimoghaddam, S., Kazemi, B., Masoudi, A., Daliri, K., Sedighi, N., 2014. Silver and gold nanostructures: antifungal property of different shapes of these nanostructures on *Candida* species. *Med. Mycol.* 52, 65–72.

27. Jia, D., Sun, W., 2021. Silver nanoparticles offer a synergistic effect with fluconazole against fluconazole-resistant *Candida albicans* by abrogating drug efflux pumps and increasing endogenous ROS. *Infect. Genet. Evol.* 93, 104937.
28. Jian, Y., Chen, X., Ahmed, T., Shang, Q., Zhang, S., Ma, Z., Yin, Y., 2022. Toxicity and action mechanisms of silver nanoparticles against the mycotoxin-producing fungus *Fusarium graminearum*. *J. Adv. Res.* 38, 1–12.
29. Joshi, K.M., Shelar, A., Kasabe, U., Nikam, L.K., Pawar, R.A., Sangshetti, J., Kale, B.B., Singh, A.V., Patil, R., Chaskar, M.G., 2022. Biofilm inhibition in *Candida albicans* with biogenic hierarchical zinc-oxide nanoparticles. *Biomater Adv* 134, 112592.
30. Kairyte, K., Kadys, A., Luksiene, Z., 2013. Antibacterial and antifungal activity of photoactivated ZnO nanoparticles in suspension. *J. Photochem. Photobiol. B* 128, 78–84.
31. Kamli, M.R., Alzahrani, E.A., Albukhari, S.M., Ahmad, A., Sabir, J.S.M., Malik, M.A., 2022. Combination effect of novel bimetallic Ag-Ni nanoparticles with fluconazole against *Candida albicans*. *J Fungi (basel)* 8, 733.
32. Karuppanan, S.K., Dowlath, M.J.H., Ramachandran, S., Rajadesingu, S., Arunachalam, K.D., 2022. 6 - Interaction of nanomaterials with microbes, in: Iqbal, H.M.N., Bilal, M., Nguyen, T.A. (Eds.), *Nano-Bioremediation : Fundamentals and Applications*. Elsevier, pp. 85-109.
33. Khojasteh-Taheri, R., Ghasemi, A., Meshkat, Z., Sabouri, Z., Mohtashami, M., Darroudi, M., 2023. Green synthesis of silver nanoparticles using *salvadora persica* and *caccinia macranthera* extracts: cytotoxicity analysis and antimicrobial activity against antibiotic-resistant bacteria. *Appl. Biochem. Biotechnol.* 195, 5120–5135.
34. Koppa Raghu, P., Bansal, K.K., Thakor, P., Bhavana, V., Madan, J., Rosenholm, J.M., Mehra, N.K., 2020. Evolution of nanotechnology in delivering drugs to eyes, skin and wounds via topical route. *Pharmaceuticals (Basel)* 13, 167.
35. Kumarasamy, R.V., Natarajan, P.M., Umopathy, V.R., Roy, J.R., Mironescu, M., Palanisamy, C.P., 2024. Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. *Front. Nanotechnol* 6, 1479993.
36. Kumari, M., Giri, V.P., Pandey, S., Kumar, M., Katiyar, R., Nautiyal, C.S., Mishra, A., 2019. An insight into the mechanism of antifungal activity of biogenic nanoparticles than their chemical counterparts. *Pestic. Biochem. Physiol.* 157, 45–52.
37. Kyriakidis, I., Tragiannidis, A., Munchen, S., Groll, A.H., 2017. Clinical hepatotoxicity associated with antifungal agents. *Expert Opin. Drug Saf.* 16, 149–165.
38. Lara, H.H., Ixtapan-Turrent, L., Jose Yacaman, M., Lopez-Ribot, J., 2020. Inhibition of *Candida auris* biofilm formation on medical and environmental surfaces by silver nanoparticles. *ACS Appl. Mater. Interfaces* 12, 21183–21191.
39. Lara, H.H., Romero-Urbina, D.G., Pierce, C., Lopez-Ribot, J.L., Arellano-Jiménez, M.J.,

Jose-Yacamán, M., 2015. Effect of silver nanoparticles on *Candida albicans* biofilms: an ultrastructural study. *J Nanobiotechnology* 13, 91.

40. Latgé, J.P., Chamilo, G., 2019. *Aspergillus fumigatus* and Aspergillosis in 2019. *Clin. Microbiol. Rev.* 33, e00140–00118.
41. Lee, K.X., Shameli, K., Yew, Y.P., Teow, S.Y., Jahangirian, H., Rafiee-Moghaddam, R., Webster, T.J., 2020. Recent developments in the facile bio-synthesis of gold nanoparticles (AuNPs) and their biomedical applications. *Int. J. Nanomed.* 15, 275–300.
42. Lee, Y., Robbins, N., Cowen, L.E., 2023. Molecular mechanisms governing antifungal drug resistance. *NPJ Antimicrob Resist* 1, 5.
43. León-Buitimea, A., Garza-Cervantes, J.A., Gallegos-Alvarado, D.Y., Osorio- Concepción, M., Morones-Ramírez, J.R., 2021. Nanomaterial-based antifungal therapies to combat fungal diseases aspergillosis, coccidioidomycosis, mucormycosis, and candidiasis. *Pathogens* 10, 1303.
44. Li, B., Pan, L., Zhang, H., Xie, L., Wang, X., Shou, J., Qi, Y., Yan, X., 2021. Recent developments on using nanomaterials to combat *Candida albicans*. *Front. Chem.* 9, 813973.
45. Liu, F., Chen, Y., Huang, Y., Jin, Q., Ji, J., 2024. Nanomaterial-based therapeutics for enhanced antifungal therapy. *J. Mater. Chem. B* 12, 9173–9198.
46. Liu, Q., Kim, Y.J., Im, G.B., Zhu, J., Wu, Y., Liu, Y., Bhang, S.H., 2021a. Inorganic nanoparticles applied as functional therapeutics. *Adv. Funct. Mater.* 31, 2008171.
47. Liu, S., Youngchim, S., Zamith-Miranda, D., Nosanchuk, J.D., 2021b. Fungal melanin and the mammalian immune system. *J Fungi (basel)* 7, 264.
48. Lopez-Moya, F., Suarez-Fernandez, M., Lopez-Llorca, L.V., 2019. Molecular mechanisms of chitosan interactions with fungi and plants. *Int. J. Mol. Sci.* 20, 332.
49. Lücking, R., Aime, M.C., Robertse, B., Miller, A.N., Aoki, T., Ariyawansa, H.A., Cardinali, G., Crous, P.W., Druzhinina, I.S., Geiser, D.M., Hawksworth, D.L., Hyde, K. D., Irinyi, L., Jeewon, R., Johnston, P.R., Kirk, P.M., Malosso, E., May, T.W., Meyer, W., Nilsson, H.R., Opik, M., Robert, V., Stadler, M., Thines, M., Vu, D., Yurkov, A.M., Zhang, N., Schoch, C.L., 2021. Fungal taxonomy and sequence-based nomenclature. *Nat. Microbiol.* 6, 540–548.
50. Madkhali, O.A., 2023. A comprehensive review on potential applications of metallic nanoparticles as antifungal therapies to combat human fungal diseases. *Saudi Pharm J* 31, 101733.
51. Makvandi, P., Wang, C., Zare, E.N., Borzacchiello, A., Niu, L., Tay, F.R., 2020. Metal-based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects. *Adv. Funct. Mater.* 30, 1910021.
52. Martínez, A., Apip, C., Meléndrez, M.F., Domínguez, M., Sánchez-Sanhueza, G., Marzalletti, T., Catalán, A., 2021. Dual antifungal activity against *Candida albicans* of copper metallic nanostructures and hierarchical copper oxide marigold-like nanostructures grown in situ in the culture medium. *J. Appl. Microbiol.* 130, 1883–1892.

53. Martins-Santana, L., Rezende, C.P., Rossi, A., Martinez-Rossi, N.M., Almeida, F., 2023. Addressing microbial resistance worldwide: challenges over controlling life-threatening fungal infections. *Pathogens* 12, 293.

54. Martins, F., Morgado, D.M., Sarmento, B., de Camargo, E.R., das Neves, J., 2023. Chitosan-based sponges containing clotrimazole for the topical management of vulvovaginal candidiasis. *Int. J. Pharm.* 647, 123508.

55. McGinnis, M.R., Tying, S.K., 1996. Introduction to Mycology, in: Baron, S. (Ed.), *Medical Microbiology*, 4th ed. The University of Texas Medical Branch at Galveston., Galveston (TX).

56. Medici, S., Peana, M., Pelucelli, A., Zoroddu, M.A., 2021. An updated overview on metal nanoparticles toxicity. *Semin. Cancer Biol.* 76, 17–26.

57. Mirza, K., Alam, D., Sardar, M., 2024. Phytosynthesized Nanoparticles: Antifungal activity and Mode of Action. In: Manzoor, N. (Ed.), *Advances in Antifungal Drug Development: Natural Products with Antifungal Potential*. Sprin

